The ABCC4 Knockout Huh-7 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal cell population engineered for loss-of-function studies of the human ABCC4 gene. This product provides a genetically disrupted ABCC4 model in the Huh-7 background through CRISPR/Cas9-mediated gene disruption, enabling researchers to interrogate the cellular roles of ABCC4 without relying on chemical inhibitors or RNA interference. The polyclonal knockout format delivers a heterogeneous pool of edited cells suitable for pooled functional assays, high-throughput screening, and pathway analysis, where monoclonality is not required.
Huh-7 is a well-characterized human hepatocellular carcinoma cell line originally established from a liver tumor of a 57-year-old Japanese male. These liver-derived epithelial cells are extensively employed as a model system for hepatocyte function, hepatitis B and C virus infection studies, drug metabolism, and hepatocellular carcinoma research. Their robust growth and retention of many hepatocyte-specific features make them a standard host for genetic manipulation aimed at deciphering molecular mechanisms underlying liver cancer pathogenesis and therapeutic resistance.
ABCC4 (ATP-binding cassette subfamily C member 4) is a multidrug resistance-associated protein that functions as an efflux transporter for diverse endobiotics and xenobiotics, including cyclic nucleotides (cAMP and cGMP), bile acids, prostaglandins, and various chemotherapeutic agents. By actively exporting these molecules, ABCC4 reduces intracellular cAMP and cGMP concentrations, thereby attenuating downstream signaling cascades mediated by PKA and PKG. The transporter is transcriptionally activated by nuclear receptors and stress-responsive factors such as NRF2, FXR, PXR, and CAR, and its expression is induced by oxidative stress, bile acids, and retinoids. Key downstream consequences of ABCC4 activity include decreased PKA signaling through CREB, dampened cGMP-PKG pathway activation, altered bile acid secretion, enhanced cellular drug resistance, and modulation of inflammatory responses via prostaglandin efflux. ABCC4 also functionally couples with CFTR in epithelial tissues and interacts with PDZ-domain scaffold proteins, integrating its transport activity into broader cellular networks.
In the hepatocellular carcinoma context, ABCC4 upregulation contributes significantly to the acquisition of chemoresistance and dysregulation of bile acid homeostasis??two hallmarks that drive tumor progression and limit therapeutic efficacy. The ABCC4 knockout Huh-7 polyclonal cells thus offer a physiologically relevant model to dissect how loss of ABCC4-mediated efflux reshapes intracellular cyclic nucleotide signaling, re-sensitizes cancer cells to cytotoxic drugs, and restores normal bile acid dynamics. This model is particularly valuable for exploring the crosstalk between antioxidant responses controlled by NRF2 and ABC transporter expression in the malignant hepatocyte environment.
This knockout product is ideally suited for a broad range of research applications, including investigation of multidrug resistance mechanisms in hepatocellular carcinoma, functional analysis of cAMP and cGMP signal transduction in liver cancer cells, and elucidation of ABCC4’s role in bile acid transport and cholestasis. It enables screening campaigns for ABCC4 inhibitors as potential chemosensitizers and facilitates the study of prostaglandin E2 efflux in inflammation-associated hepatocarcinogenesis. Representative experimental approaches compatible with this model include western blotting and RT-qPCR for ABCC4 expression validation, flow cytometric drug efflux assays using fluorescent substrates such as calcein-AM, intracellular cAMP/cGMP quantification, cell viability assays in the presence of doxorubicin or cisplatin, and bile acid transport measurements. Transcriptomic profiling by RNA-seq can further reveal global gene expression changes upon ABCC4 disruption. For further information, please contact Ascent Research.
